DIA SYS | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
DIA SYS

An SI Board Since October 2002

Posts	SubjectMarks	Bans	Symbol
1	0	0	DYX

Emcee: YAR7888	Type: Unmoderated

Introduction Market Data Compact

Press Release Source: DiaSys Corp.

DiaSys and Merck Centroamericana S.A. in Exclusive Two-Year Sales and Service Agreement
Reports Initial Orders Of 70,000 US Dollars
Tuesday October 1, 7:45 am ET

WATERBURY, Conn.--(BUSINESS WIRE)--Oct. 1, 2002--DiaSys Corporation (AMEX: DYX - News), a global healthcare products company, today announced that it has entered into an exclusive two-year sales and service agreement with Merck Centroamericana S.A., a subsidiary of Merck KGaA (XETRA: MRCG.DE - News), the world renowned pharmaceutical and chemistry products producer based in Darmstadt, Germany. Under the agreement, Merck Centroamericana S.A. will promote, sell and service DiaSys' medical equipment and consumable products in Guatemala, Honduras and Nicaragua.
Merck Centroamericana S.A. has issued initial orders to DiaSys in the amount of US$70,000 for instrumentation and consumables focused primarily on urine sediment, electrophoresis and parasite analysis applications.

Todd M. DeMatteo, DiaSys' President and CEO, said, "We are delighted to welcome Merck Centroamericana S.A. to our growing team of international distributors. For several years we have been building an international sales and service network of the highest quality and reputation into which Merck Centroamericana S.A. clearly fits. Central and South America provide significant business opportunities for our laboratory instruments and consumables and Merck Centroamericana S.A. is the ideal partner to secure our market position."

Thomas B. Schreier, Director of the Chemical Division of Merck Centroamericana S.A., added: "DiaSys' products fit very nicely into our strategy to bring modern - yet affordable and easy to handle - technology to the clinical laboratories of our countries."

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and test kits to healthcare laboratories worldwide. Headquartered in Waterbury, CT, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China.

The foregoing press release includes "forward looking statements" within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.

--------------------------------------------------------------------------------
Contact:
H.L. Lanzet, Inc.
DeeDee Lanzet/ Gerald Ortsman, 212/888-4570
or
DiaSys Corp.
Todd M. DeMatteo, 203/755-5083

--------------------------------------------------------------------------------
Source: DiaSys Corp.

Go to reply# or date (mm/dd/yy):